logo
Plus   Neg
Share
Email

Biogen's Data Shows Improved Gastrointestinal Tolerability With Vumerity

Biogen Inc. (BIIB) said that the Phase 3 EVOLVE-MS-2 study demonstrated improved patient-assessed gastrointestinal or GI tolerability of Vumerity, a new FDA-approved treatment for relapsing forms of multiple sclerosis or MS, compared to Tecfidera.
Results for the primary endpoint show patients treated with Vumerity self-reported 46 percent fewer days with intensity scores of =2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), compared to Tecfidera.

The EVOLVE-MS-2 results also indicate that compared to TECFIDERA, VUMERITY-treated patients had lower discontinuations due to GI adverse events (AEs) (0.8 percent vs. 4.8 percent).

VUMERITY is now available in the U.S. for relapsing forms of MS.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. (INTC), the world's biggest chipmaker, Thursday said its profit and revenues for the fourth quarter trumped Wall Street estimates. The company's shares gained nearly 7 percent driven by strong outlook for the first quarter and full year 2020. Santa Clara, California-based Intel reported... ABH Pharma, Inc. and Stocknutra.com Inc. have recalled all of its dietary supplement products pursuant to a consent decree entered by the U.S. District Court for the Eastern District of New York. The companies have recalled all dietary supplement products manufactured and sold between January 2013... New York-based grocery chain Fairway Market has filed for Chapter 11 bankruptcy protection, but said its stores will remain open across the Tri-State area during the court process and it does not expect any service interruptions. This is the second time the company has filed for bankruptcy. The company earlier filed for Chapter 11 bankruptcy protection in 2016.
Follow RTT
>